Sarepta, BioMarin Sign Licensing Deal

Sarepta Therapeutics and BioMarin signed a license agreement regarding exon-skipping technology and settled a patent dispute. The license agreement gives Sarepta global exclusive rights to BioMarin’s Duchenne muscular dystrophy patient database for its Exondys 51 product, which uses Sarepta’s exon-skipping technology, which allows cells to jump through faulty sections of genetic code and and all future exon-skipping products, the companies said on Tuesday.

BioMarin retains the right to convert the license to a c–exclusive right in the event it decides to proceed with an exon-skipping therapy for Duchenne muscular dystrophy. Sarepta and BioMarin also executed a settlement agreement, resolving the ongoing worldwide patent proceedings related to the use of Exondys 51 and all future exon-skipping products for the treatment of Duchenne muscular dystrophy, they said.

Leave a Comment